{"input_url":"https://www.pharmavoice.com/news/nimbus-takeda-zasocitinib-ai-drug-discovery/831289/","gnews_decode":"https://www.pharmavoice.com/news/nimbus-takeda-zasocitinib-ai-drug-discovery/831289/","http_status":200,"final_url":"https://www.pharmavoice.com/news/nimbus-takeda-zasocitinib-ai-drug-discovery/831289/","html_length":216405,"trafilatura_result":"ok","text_length":5437,"text_preview":"Takeda Pharmaceuticals’ experimental psoriasis pill zasocitinib has developed a notable track record in the clinic, including outperforming Bristol Myers Squibb’s Sotyktu in a phase 3 trial. That head-to-head result also came with another headline description: “AI-designed” drug.\nBut that characteri","verdict":"OK"}